Immunic Inc. Stock
Immunic Inc. Stock
With 17 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 6 € there is potential for a 702.14% increase which would mean more than doubling the current price of 0.75 € for Immunic Inc..
So far the community has only identified positive things for Immunic Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Immunic Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immunic Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immunic Inc. | - | - | - | - | - | - | - |
| NanoViricides Inc. | 1.520% | -1.493% | 10.000% | -8.333% | 41.935% | -3.650% | -61.062% |
| Ocuphire Pharma Inc. | -1.800% | 30.469% | -6.180% | 246.833% | 98.573% | -8.242% | -6.180% |
| Actinium Pharmaceuticals Inc. | 2.040% | -8.156% | -15.278% | -46.057% | -39.354% | -88.472% | -86.929% |
Comments
Immunic (IMUX) had its price target lowered by B. Riley Financial, Inc. from $40.00 to $27.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (IMUX) is now covered by Wolfe Research. They set an "outperform" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (IMUX) had its "buy" rating reaffirmed by Roth Mkm.
Show more
Ratings data for IMUX provided by MarketBeat
News
EQS-News: Immunic to Participate in Investor Conferences in July
EQS-News: Immunic to Participate in Investor Conferences in July
EQS-News: Immunic to Participate in Investor, Industry and Scientific Conferences in June
EQS-News: Immunic to Participate in Investor, Industry and Scientific Conferences in June
EQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
EQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis